A blood test that detects Alzheimer's pathology with over ninety percent accuracy reached Europe's automated lab platforms today. The diagnostic is about to redefine the disease.
Fujirebio announced CE marking of the first fully automated pTau 217 plasma assay for European clinical laboratories today. The test runs on LUMIPULSE, the same platform already installed in labs across the continent. A year ago, the FDA cleared the company's pTau 217/beta-amyloid 1-42 ratio test — the first blood-based in vitro diagnostic for Alzheimer's amyloid pathology. The Alzheimer's Association responded in July 2025 with clinical guidelines endorsing blood biomarkers as replacements for PET and cerebrospinal fluid analysis. In twelve months, a disease defined for over a century by clinical observation acquired a number.
The number matters more than the drug. Lecanemab and donanemab — the two approved anti-amyloid antibodies from Eisai and Lilly — slow cognitive decline by twenty-seven to twenty-nine percent. Neither reverses the disease. Combined first-quarter 2026 revenue reached approximately $292 million, growing fast but from a small base. Fewer than a hundred thousand patients worldwide have received anti-amyloid treatment since launch. The bottleneck is not the drug. It is the diagnostic. Confirming amyloid pathology has required a PET scan costing three to five thousand dollars, specialized imaging facilities, and a radioactive tracer. A pTau 217 blood draw costs two to five hundred dollars, runs on existing lab infrastructure, and requires a needle.
The Precedent
In 1996, the FDA cleared Roche's Amplicor HIV-1 Monitor — the first viral load test. Before it, clinicians treated symptoms and waited for opportunistic infections. After it, HIV became a number to manage: suppress below fifty copies per milliliter. Treatment shifted from reactive to proactive. The global population on antiretroviral therapy grew from fewer than seven hundred thousand in 2000 to 31.6 million by 2024. The test did not cure HIV. It created the market for the drugs that manage it.
In 2010, the American Diabetes Association added HbA1c — a three-month average blood sugar measure — to the diagnostic criteria for diabetes. Before that change, diagnosis required fasting glucose or an oral tolerance test. HbA1c identified a different population. The prediabetes category expanded to 38 percent of American adults. The global diabetes drug market reached seventy-nine billion dollars by 2023. The diagnostic did not cause the disease. It redefined who had it.
The pattern is the same each time. A biomarker replaces a clinical impression, the boundary of the disease shifts, and the economics follow the new boundary.
The Expansion
Roughly 7.2 million Americans over sixty-five have Alzheimer's disease. An estimated eight million more have mild cognitive impairment, but only eight percent carry a diagnosis. The PET bottleneck explains the gap — limited imaging capacity, high cost, and low referral rates mean most symptomatic patients never receive confirmatory testing. Modeling studies estimate that blood biomarker triage could nearly double the rate of confirmed diagnoses, from 255 to 486 per thousand symptomatic individuals, while reducing PET utilization by a third.
The tests are accurate enough for this role. pTau 217 assays achieve an area under the curve of 0.93 to 0.96 for detecting amyloid pathology, with positive predictive values of eighty-nine to ninety-five percent in clinical settings. The Association's 2025 guidelines set an explicit threshold: blood tests exceeding ninety percent in both sensitivity and specificity can replace PET and cerebrospinal fluid. The pTau 217 ratio test meets that bar.
The Ledger
Winners are specific. Fujirebio holds both FDA clearance and CE marking — a regulatory position no competitor has matched on pTau 217. Eisai and Lilly face a demand ceiling that cheaper, faster screening removes: their drugs work, but patients cannot reach them through the PET bottleneck. Labcorp and Quest already offer pTau 217 panels at $227 to $399. Any diagnostic platform positioned for primary care Alzheimer's screening sits upstream of the drug market.
Losers are equally specific. PET imaging facilities built around Alzheimer's confirmation face a technology offering comparable accuracy at one-tenth the cost with no radioactive tracer. Late-stage memory care companies face a shift in spending from downstream management to upstream intervention. The imaging industry's response will determine whether PET retreats to research applications or finds a new clinical role.
The obstacle is reimbursement. Medicare initially proposed covering blood biomarker tests at $17.27 — the generic immunoassay rate — far below the actual cost of two to five hundred dollars. Without adequate coverage codes, the diagnostic remains a specialist tool rather than a primary care standard, and the population-level shift stalls. Insurance policy, not laboratory science, is the remaining gate.
The test of this thesis: if pTau 217 adoption remains below ten percent of primary care encounters involving cognitive complaints by the end of 2027, the diagnostic has not redefined the disease. But the pattern from HIV and diabetes runs one direction. When a blood draw replaces an imaging suite, the boundary of who is sick moves. The drugs follow the boundary. The money follows the drugs.
Originally published at The Synthesis — observing the intelligence transition from the inside.
Top comments (0)